Interview with Patrik Eriksson, CEO Vimian

June 10, 2024

Vimian’s new CEO reflects on the evolution of animal health and the thrills of a global journey

Amidst a rapidly expanding animal health sector, Patrik Eriksson, the new CEO at Vimian, discusses the company’s strategic direction and his enthusiasm for an innovative sector with high potential.

You’ve stepped into an exciting role at a transformative time for Vimian. What does this new chapter look like for you?

When I was first approached, Vimian was new to me, but I quickly recognized the potential within the animal health market. Vimian’s solid strategy and history of quick execution resonated with me. Learning about our trajectory and witnessing first hand our commitment to innovation solidified my decision. 

As you step into the CEO role alongside a new Chair of the Board this year, what direction do you foresee for Vimian under this renewed leadership?

Leadership transitions bring new energy and perspectives. I look forward to collaborating with Magnus Welander, our new Chair of the Board. His expertise complements my vision for Vimian, and together, we will continue to build a global animal health company focused on select market niches with unmet medical needs.

The company’s recent capital injection and the move to the main market list are significant milestones. What do these developments signal for Vimian’s future?

These steps are about creating opportunities for accelerated growth and enhanced shareholder value. Transitioning to the main market opens doors to a wider investor base and necessitates higher operational standards and internal control. The SEK 1.6 billion in new funding is a testament to our shareholders’ confidence and will support our value-creative acquisitions.

What was it about Vimian that drew you to lead the company, and what opportunities excite you the most?

Vimian stands out for its strong entrepreneurial spirit and its agility in identifying and nurturing niche companies. With our presence in over 80 markets we are well positioned to connect local champions with the global market. We’ve built a platform that’s ready to lead globally, for example in orthopaedic implants for pets. I’m excited about the prospect of amplifying our impact and improve animal health —there’s a world of potential for growth and innovation in the animal health space, and I’m eager to harness it.

Looking forward, what challenges and ventures are on the horizon for Vimian?

The challenge is as thrilling as the opportunity—to influence the growth trajectory in a market with so much untapped potential. We’re in a great position to make significant strides in animal healthcare, from expanding treatment options to improving diagnostic technologies and expanding total market size as we educate 15,000 veterinary professionals annually. It’s about creating a legacy of care and progress that’s as enduring as it is transformative.

Finally, a personal note—do you have any pets at home?

I grew up with cats and have always been surrounded by animals but don’t have any pets at the moment.

Recent news

Vimian resolves on a rights issue of up to approx…

The Board of Directors of Vimian Group AB has based on the authorisation from the Annual General Meeting on 2 June 2023, resolved on a rights issue of up to approximately SEK 1,633 million. The purpose of the Rights Issue

Read more

David von Laskowski, Greenfood’s CEO, is awarde…

On the 22 of February, the winners of the “CEO of the Year” award were announced at Kistamässan in Stockholm. The winner in the Large-Cap category was David von Laskowski, Picadeli & Greenfood Group. “CEO of the Year” has been

Read more

Odevo strengthens its UK footprint as Vegner Grou…

Vegner Group Limited is a leading residential property management group in the UK with 475 employees, over 100,000 homes under management and a nationwide reach across 20 office locations. Vegner specializes in serving Residents Management Company (RMC) clients,  bringing further

Read more